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The nuclear receptor PPARa is activated by drugs to
treat human disorders of lipidmetabolism. Its endog-
enous ligand is unknown. PPARa-dependent gene
expression is impaired with inactivation of fatty
acid synthase (FAS), suggesting that FAS is involved
in generation of a PPARa ligand. Here we demon-
strate the FAS-dependent presence of a phospho-
lipid bound to PPARa isolated from mouse liver.
Binding was increased under conditions that induce
FAS activity and displaced by systemic injection of
a PPARa agonist. Mass spectrometry identified the
species as 1-palmitoyl-2-oleoyl-sn-glycerol-3-phos-
phocholine (16:0/18:1-GPC). Knockdown of Cept1,
required for phosphatidylcholine synthesis, sup-
pressed PPARa-dependent gene expression. Inter-
action of 16:0/18:1-GPC with the PPARa ligand-
binding domain and coactivator peptide motifs was
comparable to PPARa agonists, but interactions
with PPARd were weak and none were detected
with PPARg. Portal vein infusion of 16:0/18:1-GPC
induced PPARa-dependent gene expression and
decreased hepatic steatosis. These data suggest
that 16:0/18:1-GPC is a physiologically relevant
endogenous PPARa ligand.
INTRODUCTION
Peroxisome proliferator-activated receptors (PPARs) constitute
a subfamily of nuclear receptors with three current members:
PPARa, PPARg, and PPARd. Each receptor appears to modu-
late pathways at the interface between intermediary metabolism
and inflammation, making them physiologically and clinically
relevant (Bensinger and Tontonoz, 2008). PPARa is activated
by fibrate drugs to lower triglycerides and raise HDL (Barter476 Cell 138, 476–488, August 7, 2009 ª2009 Elsevier Inc.and Rye, 2008), PPARg is targeted by glitazones to treat dia-
betes (Yki-Jarvinen, 2004), and pharmacological activation of
PPARd appears to improve several metabolic parameters in hu-
mans (Riserus et al., 2008). PPARs are ligand-activated recep-
tors that heterodimerize with RXR, bind to response elements
in target genes, and alter coactivator/corepressor dynamics to
induce transcription. Fatty acids, especially if polyunsaturated,
are thought to be preferred PPAR ligands, but a wide variety of
lipids (Forman et al., 1997; Kliewer et al., 1997; Krey et al.,
1997; Yu et al., 1995) have been implicated in PPAR activation
including saturated fatty acids, fatty acyl-CoA species, eicosa-
noids (prostaglandins, leukotrienes, and HETEs), oxidized fatty
acids, and oxidized phospholipids. No endogenous PPAR ligand
has been identified.
PPARa is expressed at high levels in liver where it promotes
fatty acid oxidation, ketogenesis, lipid transport, and gluconeo-
genesis (Bernal-Mizrachi et al., 2003; Reddy and Hashimoto,
2001). Systemic levels of free fatty acids change with nutritional
status, making PPARa an attractive candidate sensor of energy
balance that might respond to fatty acids by accelerating their
metabolism. This would require that PPARa, a nuclear protein,
be exposed to concentrations of fatty acids that reflect those
outside the cell. A simple diffusion gradient for these lipids in
the hepatocyte is unlikely to exist because fatty acids crossing
the plasma membrane undergo addition of an acyl-CoA group,
leading to a myriad of potential fates including storage in lipid
droplets, synthesis of phospholipids, incorporation into intracel-
lular organelles or the external plasma membrane, transport into
mitochondria for beta oxidation, association with the ER/Golgi
for lipoprotein assembly, and others. This scheme suggests
that fatty acids are chaperoned from the extracellular environ-
ment to the nucleus to activate PPARa, or that another entity re-
flecting nutritional status is involved in generating the endoge-
nous ligand.
No chaperone has emerged for the PPARa ligand. FABP4,
which binds fatty acids, has been implicated in shuttling ligand
to another family member, PPARg (Ayers et al., 2007). FABP1,
an abundant protein in liver that binds a broad range of
fatty acids, might serve a similar function for PPARa. But
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Figure 1. Generation of Liver-Specific FAS Knockout Mice on a PPARa Null Background and Reconstitution of Liver PPARa Expression
(A) PCR analysis. Liver DNA was amplified using primer sets for the FAS floxed allele (top), PPARa (middle), and Cre (bottom).
(B) Immunoblot analysis of liver lysates for wild-type (WT) and FASKOL mice on a PPARa null background via FAS (top) and actin (bottom) antibodies.
(C and D) FAS activity (C) and malonyl-CoA content (D). Liver homogenates from overnight-fasted 12 hr chow-refed male WT and FASKOLmice on a PPARa null
background were assayed. Each bar represents mean ± SEM of 6–8 mice of each genotype. *p < 0.05.
(E) Diagram for isolation of FLAG-tagged PPARa.
(F) Immunoprecipitation (IP) and immunoblot (IB) analysis in livers of WT and FASKOL mice on a PPARa null background infected with adenoviruses encoding
GFP alone (AdGFP) or FLAG-tagged PPARa (AdFLAG-PPARa). Nuclear fractions were immunoprecipitated with FLAG antibodies and immunoblotted with either
FLAG antibody (top) or PPARa antibody (middle). Crude liver lysates were immunoblotted with actin antibody (bottom). Blots are representative of >12 indepen-
dent experiments.PPARa-dependent genes are expressed appropriately in FABP1
null mice (Newberry et al., 2003), indicating that FABP1 probably
does not present ligand to PPARa.
There is evidence that a nutritionally responsive entity may
generate the endogenous PPARa ligand. Fatty acid synthase
(FAS) catalyzes the first committed step in fatty acidbiosynthesis,
utilizing acetyl-CoA, malonyl-CoA, and NADPH to generate
mostly the saturated fatty acid palmitate (Semenkovich, 1997).
Liver-specific inactivation of FAS results in mice with decreased
PPARa-dependent gene expression and a phenotype resem-
bling PPARa deficiency (Chakravarthy et al., 2005). The pheno-
type is reversed and gene expression rescued after pharmaco-
logic activation of PPARa. This phenomenon is not limited to
the liver. Selective inactivation of FAS in the hypothalamus
impairs PPARa-dependent gene expression and alters feeding
behavior (Chakravarthy et al., 2007). Both are corrected after
hypothalamic infusion of a PPARa activator. It thus appears
that FAS, known to be regulated by nutrition, is required in
some tissues to generate the endogenous ligand for PPARa.To characterize that ligand, we developed a strategy based on
purifying a tagged PPARa molecule from the livers of mice with
or without expression of FAS. This strategy was used to test
the hypothesis that de novo lipid biosynthesis generates a phys-
iologically relevant endogenous ligand for PPARa.
RESULTS
Fatty acid synthase knockout in liver (FASKOL) mice have
impairedPPARa-dependent geneexpression that is rescued after
pharmacological activation of PPARa (Chakravarthy et al., 2005).
These mice were crossed with PPARa null mice to eliminate the
possibility of ligand competition between adenovirally transduced
PPARa and endogenous PPARa. Figure 1A shows representative
PCR genotyping assays for mice wild-type at the Ppara locus
(lane 4), Ppara heterozygotes (lane 3), and PPARa-deficient mice
used for subsequent experiments with FAS expression (lane 1,
WT PPARa/) or without FAS expression (lane 2, FASKOL
PPARa/). The fidelity of the FAS knockout in the Ppara/Cell 138, 476–488, August 7, 2009 ª2009 Elsevier Inc. 477
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Figure 2. Identification of a Glycerophosphocholine Species in FLAG-Eluted Hepatic Nuclear Extracts
Positive ion ESI/MS analyses of lithiated adducts of hepatic nuclear phospholipids were performed to monitor neutral loss of 189 [LiPO4(CH2)2N(CH3)3], which
identifies parent [MLi+] ions that contain the phosphocholine head-group in lipid mixtures.
(A–D) Representative profiles of glycerophosphocholine (GPC) species in chow-fed WT and FASKOL mice on a PPARa null background infected with AdGFP
(A and C) or AdFLAG-PPARa (B and D).
(E–H) Representative profiles of GPC species in zero-fat diet (ZFD)-fed WT and FASKOL mice on a PPARa null background infected with AdGFP (E and G) or
AdFLAG-PPARa (F and H).
Insets in (B), (D), (F), and (H) depict the fragment ion at mass-to-charge ratio (m/z) 766 as the specific GPC species that is both PPARa and FAS dependent.
(I) Quantification of the relative abundance of them/z 766 ion with respect to genotype (W/P, WT on PPARa null background; F/P, FASKOL on PPARa null back-
ground) and diet (chow and ZFD). Each bar represents mean ± SEM from 3 independent experiments with 4–6 mice in each group per experiment. *p < 0.05
versus corresponding W/P control; **p < 0.05.background was verified by demonstrating decreased FAS
protein (Figure 1B) and enzyme activity (Figure 1C) in the livers of
FASKOL mice. The FAS substrate malonyl-CoA accumulated in
FASKOL livers (Figure 1D), confirming decreased enzyme activity.
Figure 1E depicts our strategy for detecting the endogenous
PPARa ligand. Mice were treated with an adenovirus directing
expression of a FLAG-tagged PPARa under conditions that do
not induce appreciable liver inflammation as reflected by normal
liver function tests (Table S1 available online). Our reconstitution
method has been shown to achieve levels of PPARa comparable
to wild-type mice (Bernal-Mizrachi et al., 2003). Reconstitution
was followed by affinity capture (utilizing an antibody recognizing
the FLAG epitope) of PPARa under conditions (no detergent or
high salt elution buffers) unlikely to disrupt the ligand/nuclear
factor interaction. This yielded a dominant PPARa band on478 Cell 138, 476–488, August 7, 2009 ª2009 Elsevier Inc.protein-stained gels (not shown). Figure 1F shows affinity matrix
eluates subjected to immunoprecipitation followed by immuno-
blotting. These results confirm the absence of endogenous
PPARa (lanes 1 and 3) and indicate that the yield of tagged
PPARa from liver was similar inmicewith andwithout expression
of FAS (lanes 2 and 4).
Affinity matrix eluates (with equal protein content) of nuclear
fractions from mice treated with AdGFP (as a control) or
AdPPARa in the presence (WT/ PPARa/) or absence (FASKOL/
PPARa/) of FAS were subjected to mass spectrometric anal-
ysis of extracted lipids. No appreciable lipid signal was detected
fromGFP eluates (Figures 2A, 2C, 2E, and 2G for a portion of the
phospholipid spectra; triglyceride and fatty acid signalswerealso
essentially absent, data not shown), suggesting that nonspecific
binding of lipids to GFP protein was minimal.
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Figure 3. TandemMass Spectrometry Iden-
tifies the GPC Species as 1-Palmitoyl-2-
Oleoly-sn-Glycerol-3-Phosphocholine
(A) Fragmentation pattern upon collisionally acti-
vated dissociation of the ion of m/z 766, which
corresponds to the lithiated adduct [MLi+] of
16:0/18:1-GPC.
(B) Expansion of the mass spectrum in (A) from
m/z 400 to m/z 540 to illustrate relative abun-
dances of ions that represent losses of fatty acid
substitutents. The data indicate that palmitate
and oleate are the sn-1 and sn-2 substituents,
respectively.
(C) Structure of the putative PPARa ligand.We did not detect fatty acids or triglycerides bound to PPARa
that were consistent with a FAS-dependent ligand. FAS depen-
dence was assessed by isolating PPARa from mice with and
without FAS deficiency and from animals fed chow as well as
a high-carbohydrate, zero-fat diet (ZFD), as indicated by the
fact that carbohydrates induce FAS expression. PPARa triglyc-
eride binding was increased in both wild-type and FAS-deficient
livers (Figure S1), and this was more pronounced in the latter,
consistent with the hepatic steatosis that occurs with zero-fat
diet feeding in FASKOL mice. There were no genotype or diet
effects on binding of PPARa to any molecular species of
phosphatidylethanolamine or phosphatidylinositol (Figure S2),
common fatty acids (Figure S3), or lysophosphatidylcholine
(Figure S4).
Lipid analyses revealed only one peak that was FAS depen-
dent. It was observed in positive ion phospholipid spectra. Mate-
rial represented by a peak with mass to charge ratio (m/z) of
766.5 bound to PPARa purified from livers expressing FAS
(arrow, Figure 2B) and its abundance was significantly de-
creased in PPARa purified from FAS-deficient livers (arrow,
Figure 2D). The abundance of m/z 766.5 increased in PPARa
purified from WT mice fed a diet high in carbohydrates (ZFD)
(arrow, Figure 2F, compare m/z 766 to m/z 764 in Figures 2F
and 2B) but remained lowwith FAS deficiency (arrow, Figure 2H).
Quantitation of relative peak abundance in independent experi-
ments is presented in Figure 2I. Increased association of the
material represented by the ion at m/z 766 with PPARa after
high-carbohydrate feeding and its decreased detection with
FAS deficiency indicate that this material is FAS related.
Tandem mass spectrometry (Figure 3) identified this material
as the phospholipid molecular species 1-palmitoyl-2-oleoly-sn-
glycerol-3-phosphocholine (16:0/18:1-GPC). Figure 3A illus-
trates the fragmentation pattern upon collisionally activated
dissociation of the ion ofm/z 766, which corresponds to the lithi-
ated adduct [MLi+] of 16:0/18:1-GPC (Li+ permits the formation
of complexes with informative fragmentation patterns). Neutral
loss of trimethylamine [MLi+ - 59] yields an ion at m/z 707. Ions
at m/z 583 [MLi+ - 183] and m/z 577 [MLi+ - 189] reflect net
loss of [HPO4(CH2)2N(CH3)3] and of [LiPO4(CH2)2N(CH3)3],
respectively. Losses of 59, 183, and 189 are common to thetandem spectra of all GPC-Li+ species, so these ions identify
the phosphocholine head-group. The spectrum in Figure 3B
contains ions at m/z 510, m/z 504, and m/z 451 that reflect
neutral losses of palmitic acid [MLi+ - 256], the lithium salt of
palmitate [MLi+ - 262], and trimethylamine plus palmitic acid
[MLi+ - 315], respectively. The spectra also contain ions reflect-
ing losses of oleic acid (m/z 484), the lithium salt of oleate (m/z
478), and trimethylamine plus oleic acid (m/z 425). Relative
abundances of the ions at m/z 425 [MLi+ - (59 + oleic acid)]
and 451 [MLi+ - (59 + palmitic acid)] in Figure 3B indicate that
palmitate and oleate are the sn-1 and sn-2 substituents, respec-
tively, because the abundance of the ion reflecting loss of trime-
thylamine plus the sn-1 substituent always exceeds that of the
ion reflecting loss of trimethylamine plus the sn-2 substituent
(Hsu et al., 1998). Figure 3C shows a diagram of the putative
PPARa ligand based on these mass spectra.
If 16:0/18:1-GPC is an endogenous PPARa ligand, it should be
possible to competitively inhibit its binding with a known ligand in
living mice. This was demonstrated by administering 50 mg/g of
Wy14,643, a dose known to rapidly activate PPARa (Chakravar-
thy et al., 2005), at time 0, followed by isolation of PPARa-bound
lipids from the mouse livers. The putative ligand was displaced
from PPARawithin minutes of treatment with the known agonist,
both in the setting of chow (Figures 4A–4D) and zero-fat diet
(Figures 4E–4H) feeding. Note the rapid decrease in abundance
form/z 766 (representing 16:0/18:1-GPC) relative to the invariant
m/z 764 (16:0/18:2-GPC) and the increased abundance of m/z
766 at 0 min with zero-fat diet compared to chow diet. Quantita-
tion of relative peak abundance for independent experiments is
presented in Figure 4I.
Although the rapid decline in signal with Wy14,643 treatment
could represent displacement of endogenous ligand from its
binding site on PPARa, it is also possible that lipid loss could
represent accelerated metabolism because Wy14,643 activates
lipid oxidation. To distinguish between these two possibilities,
we repeated the in vivo competitive inhibition experiment by
using a PPARa molecule with a defective DNA binding domain
(Figure 5). This protein, DDBD-PPARa, should retain ligand
binding yet be incapable of increasing transcriptional programs
promoting lipid metabolism. Two cysteine residues conservedCell 138, 476–488, August 7, 2009 ª2009 Elsevier Inc. 479
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Figure 4. In Vivo Displacement of the Endogenous PPARa Ligand with a PPARa Agonist
Li+ adducts of GPCmolecular species in excess FLAG-eluted hepatic nuclear extracts obtained fromWy14,643 (Wy)-treated mice were analyzed by positive ion
ESI/MS/MS scans monitoring neutral loss of 189, which reflects elimination of lithiated phosphocholine from the parent [MLi+] ion.
(A–D) Representative ESI/MS/MS scans of GPC species at baseline (time 0) (A), 10 min (B), 30 min (C), and 60 min (D) after an intraperitoneal injection of 50 mg/g
Wy14,643 in chow-fed WT mice on a PPARa null background injected with AdFLAG-PPARa adenovirus.
(E–H) Representative ESI/MS/MS scans of GPC species at baseline (time 0) (E), 10 min (F), 30 min (G), and 60 min (H) after the same treatment in ZFD-fed mice.
Insets in (A)–(H) depict the ion at m/z 766 (16:0/18:1-GPC) that is displaced in a time-dependent manner by Wy14,643.
(I) Quantification of the relative abundance of them/z 766 ion in response to Wy14,643. Graphs represent mean ± SEM from two independent experiments with
4–5 mice in each group per experiment.in all PPAR family members were mutated to alanines in PPARa
(Figure 5A). Mutation of these residues in PPARd abolishes DNA
binding activity (Shi et al., 2002). Adenoviral expression of this
mutated protein resulted in similar levels of protein as wild-
type PPARa (Figure 5B), and DNA binding was verified to be
impaired with thismutant (DDBD in Figure 5C).Micewere treated
with AdGFP (as a control) or Ad-DDBD-PPARa in the presence
(WT/PPARa/) or absence (FASKOL/ PPARa/) of FAS and
lipids from affinity-purified nuclear extracts were then analyzed
by mass spectrometry (Figures 5D–5H). Nonspecific binding
was minimal (Figures 5D and 5F), and m/z 766 (representing
16:0/18:1-GPC) was detected with the mutant PPARa in the
presence of FAS (Figure 5E, arrow) with a substantial decrease
noted in the absence of FAS (Figure 5G, arrow). Quantitation of
relative peak abundance for independent experiments is pre-480 Cell 138, 476–488, August 7, 2009 ª2009 Elsevier Inc.sented in Figure 5H. As seen with wild-type PPARa, association
of the 16:0/18:1-GPC represented by the ion at m/z 766 with
DDBD-PPARa was reduced within minutes of administration of
Wy14,643 to mice (Figures 5I–5L). Competitive inhibition data
from independent experiments are presented in Figure 5M.
These results confirm that 16:0/18:1-GPC binding to PPARa is
FAS dependent and involves a binding site that is also occupied
by a known PPARa activator.
Rapid displacement of 16:0/18:1-GPC by the synthetic ligand
Wy14,643 might reflect a relatively lower affinity of 16:0/18:1-
GPC for PPARa as compared to other receptor-associated
species that were not displaced, such as 16:0/18:2-GPC (m/z
764) and 18:1/18:1-GPC (m/z 793). To address this possibility,
we performed luminescent proximity (AlphaScreen) assays as
well as scintillation proximity assays (Nichols et al., 1998)
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Figure 5. Generation of a PPARa DNA Binding Domain Mutant Adenovirus and Mass Spectrometric Analysis
(A) Schematic of the modular domain structure of PPARa (top). AF, activating function; LBD, ligand binding domain. The two highly conserved cysteine residues
(blue) within the DBD of the PPAR family (bottom) were mutated to alanine (red).
(B) Immunoblot analysis of Cos-7 cells transfected with empty vector, wild-type (WT), or DNA binding domain (DBD) mutant (DDBD) PPARa plasmids via anti-
PPARa and proliferating cell nuclear antigen (PCNA) antibodies. Gels are representative of three independent experiments.
(C) Mutation C119A, C122A disrupts PPARaDNA binding activity. Cos-7 cells were transfected and DNA binding activity was assayed. Graphs represent mean ±
SEM of experiments performed in triplicate. *p < 0.05 versus empty vector. #p < 0.05 versus WT control.
(D–G) Representative positive ion ESI/MS/MS scans monitoring neural loss of 189 from lithiated adducts of GPC species in FLAG-eluted hepatic nuclear extracts
obtained from chow-fedWT and FASKOLmice on a PPARa null background infected with AdGFP (D and F) or AdDDBDPPARa (E and G) adenoviruses. Insets in (E)
and (G) indicate that thematerial represented by the ion atm/z 766 is the FAS-dependent phospholipidmolecular species. A tandem spectrum of this ion (Figure 3)
establishes its identity as [MLi+] of 16:0/18:1-GPC.
(H) Quantification of the relative abundance of them/z 766 ion in response to control andmutant adenoviral injections inW/P (WT on PPARa null background) and
F/P (FASKOL on PPARa null background) mice. Each bar represents the mean ± SEM from three independent experiments with 4–6 mice in each group per
experiment. *p < 0.05 versus corresponding W/P control.
(I–L) Representative neutral loss of 189 ESI/MS/MS scans of GPC species at baseline (time 0) (I), 10min (J), 30min (K), and 60min (L) after intraperitoneal injection
of 50 mg/g Wy14,643 in chow-fed WT mice on a PPARa null background injected with AdDDBD PPARa adenovirus. Insets in (I)–(L) indicate that the ion atm/z 766
(16:0/18:1-GPC) is displaced from the DBD-defective PPARa in a time-dependent manner by Wy14,643.
(M) Quantification of the relative abundance of the m/z 766 ion in response to Wy14,643 administration in WT mice on a PPARa null background injected with
AdDDBD PPARa adenovirus. Graphs represent mean ± SEM from two separate experiments with 3–4 mice in each group per experiment.involving concentration-dependent displacement of radiola-
beled Wy14,643. Binding constants of 16:0/18:1-GPC, 16:0/
18:2-GPC, and 18:1/18:1-GPC for PPARa were identical and,
as expected, indicated a lower affinity of these phospholipids
for PPARa than Wy14,643 (Figure S5). These results are consis-
tent with the notion that the in vivo displacement of 16:0/18:1-GPC by Wy14,643 represents competition of a higher-
affinity synthetic ligand for an endogenous ligand.
The binding of 16:0/18:1-GPC to PPARawas decreased in the
absence of FAS and significantly increased under conditions
(high-carbohydrate feeding) that induce FAS activity (see
Figure 2I), suggesting that FAS is involved in the generation ofCell 138, 476–488, August 7, 2009 ª2009 Elsevier Inc. 481
this ligand. Total hepatic nuclear concentrations of 16:0/18:1-
GPC, 16:0/18:2-GPC, and 18:1/18:1-GPC were assayed by
mass spectrometry under fed and fasting conditions (Table
S2). 16:0/18:1-GPC and 16:0/18:2-GPC tended to increase
with fasting, but these differences were not significant. These
assays represent measurements of the total content of a partic-
ular phospholipid in the nucleus, not phospholipid bound to
PPARa or phospholipid available for signaling. Relevant endog-
enous ligands should fluctuate during metabolic transitions but
current techniques require use of the entire nucleus, which
includes a considerable mass of structural GPCs comprising
nuclear membranes. The predominant mass of structural
GPCs likely overwhelms any changes in the smaller mass of
GPCs that might serve a signaling role by liganding nuclear
receptors. Assaying the entire nucleus did, however, allow the
determination of the relative abundance of 16:0/18:1-GPC. The
contribution of 16:0/18:1-GPC to total nuclear phosphatidylcho-
line in mouse liver was 11.4% ± 0.6% and its contribution to total
nuclear phospholipids was 4.4% ± 1.2%.
Ligand-dependent activation of PPARa induces expression of
genes involved in fatty acidmetabolism such as acyl-CoA oxidase
and the liver isoformofcarnitinepalmitoyl transferase1 (Acox1and
Cpt1a). Incubation of culturedmouse hepatoma cells with exoge-
nous 16:0/18:1-GPC (the FAS-dependent phosphatidylcholine
species) increasedexpressionofbothAcox1andCpt1a toasimilar
degree as equimolar amounts of the known PPARa activator
Wy14,643 (Figure S6). However, the link between FAS and PPARa
is most likely to be mediated by effects on endogenous phospha-
tidylcholine synthesis, which occurs mostly through the Kennedy
pathway (Figure 6A). Endogenous synthesis involves the succes-
siveactionof choline kinase (CK)andCTP:phosphocholinecytidy-
lyltransferase (CCT) to yield CDP-choline (Kent, 2005). This
substrate reacts with diacyglycerol (DAG) to yield phosphatidyl-
choline (PtdCho) through theactionofoneof twoenzymes,choline
phosphotransferase 1 (ChPT1), found in the Golgi, and choline-
ethanolamine phosphotransferase-1 (CEPT1), found in the nu-
cleus as well as the ER (Henneberry et al., 2002). siRNA-mediated
knockdown of these enzymes was achieved in cultured mouse
hepatoma cells (Figure 6B), followed by assessment of PPARa-
dependent genes. Inactivation of ChPT1, the Golgi enzyme, had
no effect on Acox1 or Cpt1a (Figure 6C). However, knockdown
of CEPT1, the nuclear/ER enzyme, decreased PPARa-dependent
genes, an effect that was rescued by exogenous 16:0/18:1-GPC
(Figure 6D), consistent with the notion that endogenous 16:0/
18:1-GPC activates PPARa and that FAS-dependent 16:0/18:1-
GPC is an endogenous PPARa ligand.
Two additional pieces of evidence support the link between
CEPT1 and induction of PPARa-dependent genes. Overexpres-
sion of CEPT1 in hepatoma cells increased expression of Acox1
and Cpt1a (Figure 6E). We also generated an adenovirus ex-
pressing an shRNA for CEPT1. Treatment of living mice with
this virus decreased Cept1 expression in liver (Figure 6F, top).
Livers with decreased Cept1 expression were pale appearing
and had increased Oil Red O staining (insets). This intervention
resulted in decreased expression of the PPARa-dependent
genes Acox1 and Cpt1a (Figure 6F, bottom).
Luminescent proximity (AlphaScreen) assays showed that
equimolar amounts of 16:0/18:1-GPC and the known potent482 Cell 138, 476–488, August 7, 2009 ª2009 Elsevier Inc.PPARa activator GW7647 exhibited similar patterns of interac-
tion with the PPARa ligand binding domain (LBD) and a series
of coactivator peptides (Figure 6G). Nearly identical interaction
signals with the PPARa LBD were also seen when equimolar
amounts of Wy14,643 and 16:0/18:1-GPC were compared
(data not shown). As compared to the PPARd activator
GW0742 (Figure 6H), interactions between 16:0/18:1-GPC and
the PPARd LBD were weak, and no signal was detected with
the PPARg LBD as compared to the positive control rosiglita-
zone (Figure 6I).
To provide in vivo evidence that 16:0/18:1-GPC serves as
a PPARa endogenous hepatic ligand, we implanted catheters
in the portal veins of mice, infused this phosphatidylcholine
species or vehicle over several days, fasted the animals (while
continuing the infusions), then isolated their livers for assays of
fat content as well as gene expression. Direct portal vein infusion
was prompted by preliminary results showing that intraperito-
neal administration of 16:0/18:1-GPC had no effect (data not
shown). In additional preliminary experiments, kinetic analyses
of radiolabeled phosphatidylcholine showed selective nuclear
enrichment within minutes of portal vein administration (Fig-
ure S7). The appearance of the catheter in the portal vein (pv-
cath) is shown in Figure 7A. Our treatment protocol is shown in
Figure 7B. After recovering from catheter placement, mice
were started on a zero-fat diet (ZFD) and treated with thrice-daily
infusions of phosphatidylcholine or vehicle between days 4 and 9
followed by a prolonged fast (while continuing the infusions).
Fasting causes fatty liver in mice, an effect that is amplified in
PPARa null mice. Fat staining of liver is shown in Figure 7C
and liver triglyceride quantified in Figure 7D. Lipid content of
PPARa-deficient mice was increased as compared to controls
and unaffected by phosphatidylcholine infusion. Fat content
was decreased in control (C57/BL6) mice with infusion of 16:0/
18:1-GPC as compared to vehicle. The PPARa-dependent
genes Acox1 and Cpt1a were increased by 16:0/18:1-GPC in
control mice but not in PPARa-deficient mice (Figure 7E).
DISCUSSION
PPARs are targets of drugs in use and in development to treat
disease, and they modulate metabolic and inflammatory path-
ways by responding to nutritional signals through ligand activa-
tion of transcription. No authentic endogenous PPAR ligand,
the molecule occupying the nuclear receptor binding site
in vivo while the receptor is actively driving transcription, has
been identified. Here we demonstrate PPARa binding of a
discrete phospholipid, 16:0/18:1-GPC, in mammalian liver in
the presence of FAS, when PPARa is active, but not in the
absence of FAS, when PPARa is not. This molecule was dis-
placed from PPARa in vivo with a pharmacological ligand, inhib-
iting its biosynthesis in cells and living mice disrupted PPARa-
dependent gene expression and infusing it directly into mouse
liver, altered hepatic lipid metabolism in a PPARa-dependent
fashion. These results suggest that this particular phosphatidyl-
choline species is a physiologically relevant endogenous PPARa
ligand in liver.
There is precedent for the interaction of phospholipids with
nuclear receptors. The crystal structure of the insect homolog
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Figure 6. Gene Expression and Binding Assays
(A) Schematic of the Kennedy pathway to generate phosphatidylcholine (PtdCho). CK, choline kinase; CTP, cytosine triphosphate; CCT, CTP phosphocholine
citidyltransferase; DAG, diacyl glycerol; ChPT1, choline phosphotransferase 1; CEPT1, choline-ethanolamine phosphotransferase 1.
(B) Effect on ChPT1 (Chpt1) and CEPT1 (Cept1) mRNA levels normalized to L32 ribosomal mRNA (Rp132) in response to 72 hr treatment with corresponding
siRNAs and scrambled (Scr) controls in Hepa 1-6 cells.
(C) Effect of 72 hr treatment with scrambled and ChPT1 siRNAs on PPARa target genes Acox1 and Cpt1a (ACO and CPT-1) by RT-PCR normalized to L32 ribo-
somal mRNA in Hepa 1-6 cells.
(D) Effect of 72 hr treatment with scrambled and CEPT1 siRNAs on Acox1 andCpt1amessage levels in Hepa 1-6 cells. Expression of Acox1 and Cpt1a (ACO and
CPT-1) was also assessed 24 hr after addition of 50 mM 16:0/18:1-GPC in a subset of Hepa 1-6 cells previously treated with CEPT1 siRNA. mRNA levels are
normalized to control L32 ribosomal mRNA. For (C)–(E), graphs represent mean ± SEM of three separate experiments with each group in triplicate. *p < 0.05
compared to scrambled controls. #p < 0.05 compared to CEPT1 siRNA-treated cells.
(E) Effect of CEPT1 overexpression on Acox1 and Cpt1a (ACO and CPT-1) message levels in Hepa 1-6 cells. Cells were transfected with a human CEPT1 expres-
sion vector, and expression was documented by the RT-PCR reaction shown in the inset (lane 1, ladder; lane 2, cells transfected with empty vector; lane 3, cells
transfected with the human CEPT1 vector). Graphical results are normalized to L32 mRNA. *p < 0.05 compared to vector.
(F) Effect of Cept1 knockdown in living mice. C57BL/6 mice were treated with an shRNA adenovirus for CEPT1 or a control virus expressing GFP. shRNA treat-
ment resulted in decreased expression of Cept1 (top) and livers showed increased staining by Oil Red O (ORO). shRNA-treated livers also showed decreased
expression of Acox1 and Cpt1a (ACO and CPT-1; bottom). Results are normalized to L32. *p < 0.05 compared to GFP treatment.
(G–I) Binding of various peptide motifs to the purified PPARa (G), PPARd (H), and PPARg (I) LBD in the presence of 5 mM of the corresponding PPAR agonist or
16:0/18:1-GPC as measured by AlphaScreen assays. The background signals of either the respective LBDs or the peptides alone, or without addition of the
ligand/agonist (no compound), are all less than 800. Data represent mean ± SEM from three separate experiments.of mammalian RXR includes copurified phospholipid (Billas
et al., 2001; Clayton et al., 2001). Structures of the ligand binding
domains of two orphan receptors, SF-1 and LRH-1, include elec-
tron density patterns representing phospholipids (Krylova et al.,2005; Li et al., 2005; Ortlund et al., 2005). In contrast to PPARa,
which forms heterodimers with RXR and is clearly ligand acti-
vated, SF-1 and LRH-1 bind to DNA as monomers and it is not
known whether the ligands for these receptors are involved inCell 138, 476–488, August 7, 2009 ª2009 Elsevier Inc. 483
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Figure 7. Portal Vein Infusion of 16:0/18:1-GPC Rescues Hepatic Steatosis in a PPARa-Dependent Manner
(A) Operative field depicting the portal vein (PV) cannulated with a catheter (pv-cath) positioned at the entry site into the liver (lvr). The catheter is intentionally
marked in black ink at its proximal tip to enhance visualization. Labels indicate gall bladder (gb), bile duct (bd), inferior vena cava (ivc), and pancreas (pan).
(B) Intraportal 16:0/18:1-GPC treatment protocol. After insertion of the portal vein catheter, C57BL/6 mice (wild-type for FAS and either wild-type or null for
PPARa) were allowed to recover. On day 4, chow was changed to a zero-fat diet (ZFD) and the mice received three intraportal injections/day of 10 mg/kg
16:0/18:1-GPC sonicated in normal saline/0.5% ethanol/0.5% fatty acid-free BSA or vehicle alone. On the last day before the end of treatment (day 9), mice
were fasted for 24 hr.
(C) At the end of the treatment protocol, liver histological sections were stained with oil red O to visualize neutral lipids (340 magnification) from wild-type (C57/
BL6) and PPARa/ mice treated with 16:0/18:1-GPC or vehicle (Veh). Sections are representative of several animals for each condition.
(D) Quantification of hepatic triglyceride content per unit mass of tissue from vehicle and 16:0/18:1-GPC treated C57/BL6 and PPARa/mice. Scale bars repre-
sent mean ± SEM of two separate infusion experiments with 5–8 animals per group in each experiment. *p < 0.05 versus corresponding Veh. #p < 0.05 versus
C57/BL6 controls.
(E) Expression of hepatic Acox1 (ACO; top) and Cpt1a (CPT-1; bottom) mRNA by RT-PCR normalized to control L32 ribosomal mRNA after the 16:0/18:1-GPC
injections. Data representmean ±SEMof two independent RT-PCR experiments for each genewith 4mice per genotype per group. *p < 0.05 versus correspond-
ing Veh. #p < 0.05 versus C57/BL6 controls.
(F) Proposed model for the generation of the endogenous PPARa ligand in liver. FAS yields palmitate (C16:0), and 16:0/18:1-GPC is likely generated through the
diacylglycerol (DAG) intermediate and the enzymatic activity of CEPT1 either in the ER or the nucleus. Binding of 16:0/18:1-GPC to PPARa in the nucleus activates
transcription machinery (TM) turning on PPARa-dependent genes and affecting hepatic lipid metabolism. ACC, acetyl CoA carboxylase; ER, endoplasmic retic-
ulum.dynamic regulation of their activity (Forman, 2005). Oxidized
phospholipids, especially those derived from modified low-
density lipoprotein particles through the action of phospholi-
pases or lipoxygenases, have been implicated in the activation
of PPARa and PPARg (Davies et al., 2001; Delerive et al.,
2000; Lee et al., 2000).484 Cell 138, 476–488, August 7, 2009 ª2009 Elsevier Inc.Our current results show that the phosphatidylcholine molec-
ular species 16:0/18:1-GPC binds PPARa at an activating ligand
binding site (reflected by its displacement with a synthetic
PPARa ligand in vivo) when FAS enzyme activity is present.
16:0/18:1-GPC is the only FAS-dependent phosphatidylcholine
species we identified bound to PPARa in vivo. However, two
other phosphatidylcholine species, 16:0/18:2-GPC and 18:1/
18:1-GPC, were also copurified with tagged PPARa from liver,
and their interactions with the PPARa ligand binding domain
in vitro (Figure S5) were indistinguishable from those of 16:0/
18:1-GPC. The failure to discriminate between these three
GPCs in vitro may be due to differential interactions between
ligands and ligand-binding domains in vitro as opposed to
ligands and full-length receptors in vivo. 16:0/18:2-GPC and
18:1/18:1-GPC, but not 16:0/18:1-GPC, remained bound to
PPARa in the absence of hepatic FAS, a condition characterized
by a striking decrease in PPARa-dependent gene expression.
Their association with the receptor in the absence of appropriate
activation of gene expression suggests that the binding of 16:0/
18:2-GPC and 18:1/18:1-GPC is not sufficient for receptor acti-
vation, but we cannot exclude the possibility that the presence of
these additional species may be necessary for receptor activa-
tion.
In AlphaScreen assays, 16:0/18:1-GPC interactedwith PPARa
but not PPARg, suggesting that this species does not bind
nonspecifically to PPARs and consistent with data showing
that 16:0/18:1-GPC does not interact with the ligand-binding
domains of PPARg, SF-1, or LRH-1 (Krylova et al., 2005). One
interpretation of our findings is that FAS, which synthesizes
predominantly the saturated fatty acid palmitate (16:0), preferen-
tially channels newly synthesized palmitate through diacylgly-
cerol to the site of phosphatidylcholine synthesis for generation
of the PPARa ligand. Previous data also link fatty acid synthesis
and phosphatidylcholine synthesis. In cultured cells, SREBPs
stimulate the synthesis of phosphatidylcholine (but not other
phospholipids), and this effect is attenuated by the FAS-inhibitor
cerulenin (Ridgway and Lagace, 2003). Figure 7F shows how
fatty acid synthesis, phosphatidylcholine synthesis, and PPARa
signaling appear to be related based on the current findings.
In the current work, addition of 16:0/18:1-GPC to cultured cells
increased PPARa-dependent gene expression (Figure S6), its
addition rescued PPARa-dependent gene expression when
endogenous synthesis of phosphatidylcholine was interrupted
(Figure 6D), and its infusion directly into the portal vein of living
mice increased PPARa-dependent genes and corrected fast-
ing-induced steatosis only in the presence of PPARa (Figures
7A–7E). These experiments support the concept that this GPC
species activates PPARa, but they do not show that a circulating
form of this lipid reports nutritional status. In fact, how altering
extracellular concentrations of a charged phospholipid species
might affect nuclear events is unknown, although there is
evidence that certain extracellular phospholipids have direct
access to the nuclear receptor PPARg (Davies et al., 2001).
Our results showing that portal vein infusion results in nuclear
before cytoplasmic accumulation (Figure S7) are consistent with
an uncharacterized conduit for phospholipids to the nucleus.
Because the portal vein drains the intestine, the anatomic origin
of nutrients, the results also suggest that providing a GPC ligand
in the diet, if it were able to access the portal vein at sufficient
concentrations, could activate hepatic PPARa. The method of
infusion, utilizing the portal vein, is likely important. FASKOL
mice have elevated circulating levels of fatty acids (in the periph-
eral venous circulation) that contribute to the hepatic steatosis of
these animals (Chakravarthy et al., 2005). Curiously, these fattyacids (so abundant that they cause fatty liver) from the periphery
(that we have referred to as ‘‘old ’’ fat as opposed to ‘‘new’’ fat
from de novo lipogenesis or diet) are unable to activate PPARa,
suggesting (based on the current work) that they are unavailable
for GPC synthesis. Lipids from the periphery enter the liver via
the hepatic artery whereas those from the diet enter via the portal
vein. The hepatic artery and portal vein comprise anatomically
distinct regions of the portal triad, and it is possible that hepato-
cytes in those different segments respond differently to lipid
signals.
Although the infusion studies provide proof of principle that
16:0/18:1-GPC can affect liver biology in a PPARa-dependent
manner, they are not directly germane to the central finding of
this paper that the intracellular enzyme FAS is linked to the
generation of a physiologically relevant endogenous ligand for
PPARa. However, the infusion studies represent grounds for
future research involving portal vein infusions as well as dietary
supplementation with GPCs labeled at different substituents to
further pursue the notion that an externally provided GPC can
reach PPARa intact.
Modulating phospholipids is also complicated by remodeling,
a process identified by Lands (Lands, 1960) that results in the re-
arrangement of fatty acid substituents. Not all of the responsible
enzymes have been identified, but PPARa activation induces the
expression of a recently discovered lysophosphatidylcholine
acyltransferase (LPCAT3) in liver that remodels the sn-1 and
sn-2 fatty acid substituents (Zhao et al., 2008) and might repre-
sent a mechanism for dampening phosphatidylcholine-medi-
ated activation of PPARa.
Phosphatidylcholine is ubiquitous in the cell and comprises
a substantial proportion of the nuclear volume. It would have
a limited capacity to regulate PPARa if high nuclear concentra-
tions ensured constant occupation of the ligand binding site,
but the putative PPARa ligand we identified, 16:0/18:1-GPC, is
a minor PtdCho species in liver as shown by the current work
(Results) and previous work (Hsu et al., 1998), consistent with
a signaling role for this molecule. Conversely, 16:0/18:1-GPC is
the most abundant PtdCho in brain (Hsu et al., 1998), raising
the possibility that a different PtdCho species may activate
PPARa in this tissue.
Both PPARa activation and phosphatidylcholine are thought
to be anti-inflammatory (Cuzzocrea et al., 2004; Li et al., 2006;
Straus and Glass, 2007; Stremmel et al., 2007; Treede et al.,
2007). Based on our findings of a discrete PtdCho molecular
species serving as a hepatic ligand for PPARa, tissue-specific
phospholipid ligands, either induced endogenously or perhaps
provided in the diet, could modify inflammatory processes so
that off-target side effects are minimized.
EXPERIMENTAL PROCEDURES
Animals and Reagents
Animal protocols were approved by the Washington University Animal Studies
Committee. Mice were genotyped using previously described primer sets
(Bernal-Mizrachi et al., 2003; Chakravarthy et al., 2005) and fed either chow
(Purina 5053) or a zero-fat diet (ZFD) (Harlan Teklad, TD03314). Experiments
were performed at 16–20 weeks of age to allow for maximal effects of
albumin-Cre. Assays were performed as described (Chakravarthy et al.,
2005). 1-Palmitoyl-2-Oleoyl-sn-Glycero-3-Phosphocholine (PC16:0/18:1) andCell 138, 476–488, August 7, 2009 ª2009 Elsevier Inc. 485
its regioisomer, 1-Oleoyl-2-Palmitoyl-sn-Glycero-3-Phosphocholine (PC18:1/
16:0) were obtained from Avanti Polar Lipids (Alabaster, AL). Stealth siRNA
oligonucleotides for mouse ChPT1 (GGAGGAGCAACAAUGUGGGACUAUA)
and CEPT1 (UGGCAGUGAUUGGAGGACCACCUUU) were from Invitrogen
(Carlsbad, CA).
Isolation of Tagged PPARa
Freshly harvested livers (100 mg) were gently homogenized in ice-cold non-
detergent hypotonic buffer (10 mM HEPES [pH 7.9], 1.5 mM MgCl2, 10 mM
KCl, 100mMDTT, protease and phosphatase inhibitor cocktail). After an addi-
tional 10 min incubation in the hypotonic buffer, the homogenate was centri-
fuged at 8000 3 g at 4C for 20 min. The pellet was homogenized in ice-cold
extraction buffer (10 mM HEPES [pH 7.9], 1.5 mM MgCl2, 0.21 M NaCl,
0.2 mM EDTA, 25% (v/v) glycerol, 100 mM DTT, protease and phosphatase
inhibitor cocktail), placed on a rotating shaker at 4C for 1 hr, then centrifuged
at 18,0003 g for 10min. The supernatant (nuclear fraction) was incubated with
anti-FLAGM2-Agaroseaffinity gel (A2220, Sigma) overnight at 4Cona rotating
shaker. Four washes (50 mM Tris HCl [pH 7.4], 100 mM NaCl, protease and
phosphatase inhibitor cocktail) were followed by elution with competition
with excess 33 FLAG peptide (F4799, Sigma; 150 ng/ml). An aliquot of the
complex was processed for immunoblotting; the remainder was transferred
to methanol/chloroform and processed for mass spectrometry.
Electrospray Ionization Mass Spectrometry
Phosphatidylcholine (GPC), lysophosphatidylcholine (LPC), sphingomyelin
(SM), and ceramide (CM) were analyzed as Li+ adducts by positive ion ESI/
MS on a Finnigan (San Jose, CA) TSQ-7000 triple-stage quadrupole mass
spectrometer with an ESI source controlled by Finnigan ICIS software. Lipids
were dissolved in methanol/chloroform (2/1, v/v) containing LiOH (10 pmol/ml),
infused with a Harvard syringe pump, and analyzed as described (Hsu et al.,
1998, 2003; Hsu and Turk, 2000, 2003). For tandem MS, precursor ions
selected in the first quadrupole were accelerated into a chamber containing
argon to induce collisionally activated dissociation, and product ions were
analyzed in the final quadrupole. Constant neutral loss scanning was per-
formed to monitor GPC [M+Li]+ ions that undergo loss of 183 or 189 (phospho-
choline or its Li+ salt) and similar scanswere performed tomonitor LPC and SM
[M+Li]+ ions that undergo loss of 59 (trimethylamine) and to monitor CM
[M+Li]+ ions that undergo loss of 48 (water plus formaldehyde). Intensities of
ions for internal standards were compared to those of ions for endogenous
species followed by interpolation from calibration curves. Glycerophospho-
ethanolamine, -glycerol, -serine, and -inositol were analyzed as [M-H] ions
by negative ion ESI/MS/MS relative to internal standards (Nowatzke et al.,
1998; Ramanadham et al., 1998) and their tandem spectra were obtained.
DNA Binding Activity
Cos-7 cellsmaintained in DMEMcontaining 10% fetal bovine serumwere tran-
siently transfected with 2 mg of wild-type and DBDmutant-PPARa plasmids by
using FuGENE6 (Roche) as described (Lodhi et al., 2007). Nuclear extract DNA
binding activity was determined with the PPARa transcription factor assay kit
(Cayman Chem, Inc.).
Mouse Hepatocytes
The C57BL/6 mouse hepatoma cell line Hepa 1-6 (ATCC, CRL-1830) was
expanded in DMEM with 10% fetal bovine serum. For experiments, cells
were cultured to 50%–60% confluence and washed twice with PBS, and the
medium was changed to serum-free DMEM supplemented with the various
types and concentrations of phosphatidylcholine (sonicated to homogeneity
in PBS/1% ethanol/4% fatty acid-free BSA), Wy14,643 (dissolved in 80%
PBS/20% DMSO), or vehicle-only solutions. 24 hr later, cells were washed,
RNA prepared, and Acox1 and Cpt1a expression levels were determined by
quantitative RT-PCR. For siRNA experiments, 50%–60% confluent cells were
treated with siRNAs or their scrambled controls (all diluted in PBS) for 72 hr.
After the 72 hr siRNA treatment, another set of cells received 16:0/18:1-GPC
(with a concentration based on dose-response experiments) for an additional
24 hr. For overexpression of CEPT1, cells were transfected with a vector con-
taining human CEPT1 cloned in the pCMV6-XL4 plasmid (Origene, Rockwell,
MD) with Lipofectamine 2000 (Invitrogen). After 24 hr, RNA was isolated.486 Cell 138, 476–488, August 7, 2009 ª2009 Elsevier Inc.CEPT1 shRNA Adenovirus
pLKO.1 plasmid (TRCN0000103315) encoding mouse Cept1 shRNA under
control of the U6 promoter was obtained from Open Biosystems (Huntsville,
AL). The shRNA sequence is ccggCCCATCCTATAAACTGAATATctcgagATA
TTCAGTTTATAGGATGGGtttttg.
To construct the Cept1 knockdown adenovirus, the shRNA expression
cassette from the pLKO.1 plasmid was subcloned into the Dual-Basic adeno-
viral shuttle vector and recombinedwith Ad5 (DE1/DE3) vector (Vector Biolabs,
Philadelphia, PA). The adenovirus was packaged in HEK293 cells and purified
with cesium chloride ultracentrifugation. The knockdown virus or a control
adenovirus expressing GFP was administered at 83 109 PFU in a total volume
of 200 ml. On day 5 after injection, animals were sacrificed and livers were
harvested.
PPAR Binding Assays
Binding of 16:0/18:1-GPC and known agonists to the ligand binding domain
(LBD) of PPARa in the presence of various peptide motifs was determined
by AlphaScreen assay (Pioszak and Xu, 2008). Experiments used 100 nM
receptor LBD, purified as 63 His tag fusion proteins (Li et al., 2005), and
20 nM of N-terminal biotinylated CBP1 peptide or other coactivator peptides
in the presence of 5 mg/ml donor and acceptor beads in 50 mM MOPS
(pH 7.4), 100 mM NaCl, and 0.1 mg/ml BSA for 90 min at 25C. Signals were
generated in the absence or the presence of ligand. Identical experiments
were performed with the PPARd and PPARg LBDs.
Portal Vein Infusion
Portal veins were cannulated as described (Strubbe et al., 1999). The catheter
(0.025 mm OD 3 0.012 mm ID, Braintree Scientific), prefilled with 55% (w/v)
polyvinylpyrrolidone (Sigma) in heparin (100 IU/ml saline) to prevent clotting,
was anchored to the abdominal wall, and its free end was inserted under the
skin and tunneled to a small midline incision slightly distal to the scapula on
the back. Body weight and food intake returned to baseline levels (usually
by day 3) before experiments. Starting on post-op day 4, animals were fed
a zero-fat diet (TD 03314, Harlan Teklad) for 5 days, which induces modest
to severe hepatic steatosis in C57BL/6 and PPARa/ mice, respectively.
During this period, animals received three intraportal infusions a day of either
10 mg/kg phosphatidylcholine (16:0/18:1-GPC) sonicated to homogeneity in
a 37C solution of saline/0.5% ethanol/0.5% fatty acid-free BSA, or vehicle
alone, based on appropriate time course and dose-response preliminary
experiments (see Supplemental Experimental Procedures). Animals were
then fasted for 24 hr, and livers were harvested.
Statistical Analyses
Comparisons were performed with an unpaired, two-tailed Student’s t test or
analysis of variance (ANOVA). If the overall F was significant for the latter,
comparisons between means were made with appropriate post hoc tests.
SUPPLEMENTAL DATA
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